NCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
Clinical Trials
6 trialsNCT01326689 2017-03-08
2246-004
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00236041 2014-05-09
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01842893 2013-05-03
ETHYFYL
Ethypharm
Phase 3 Completed
NCT00842829 2012-10-01
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 4 Terminated
NCT00576173 2010-04-28
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Johnson & Johnson Taiwan Ltd
Phase 4 Completed